Orris

Introduction of thesis with review of literature

Asking for Preferences
Asking for Preferences

Comparative Study of Ropivacaine Epidural Infusion versus Dexmedetomidine Infusion for Postoperative Pain Management and Hemodynamic Stability in Open Urological Surgeries

Reading File
Finding Sources
Finding Sources
Searching PubMed

ropivacaine epidural AND dexmedetomidine AND postoperative analgesia

Searching PubMed

dexmedetomidine infusion AND postoperative pain AND urological surgery

Finding Sources
Finding Sources
Searching PubMed

ropivacaine epidural analgesia postoperative abdominal surgery hemodynamic

Searching PubMed

postoperative pain management open urological surgery nephrectomy cystectomy

Reading File
Reading File
Reading File
Reading File
Reading File
Searching PubMed

dexmedetomidine intravenous infusion postoperative analgesia hemodynamic stability

Reading Article

PMID: 42029950

Reading Article

PMID: 35320957

Reading Article

PMID: 36171946

Reading Article

PMID: 37404259

Reading Article

PMID: 40755581

Finding Sources
Here is the complete draft of your thesis chapters, grounded in authoritative textbooks (Miller's Anesthesia, Barash's Clinical Anesthesia, Goodman & Gilman's Pharmacology, Maingot's Abdominal Operations) and peer-reviewed literature.

CHAPTER 1: INTRODUCTION

1.1 Background

Postoperative pain remains one of the most clinically challenging aspects of perioperative care. It is a universal sequel of surgical trauma and, if inadequately controlled, contributes to a cascade of adverse physiological consequences including impaired respiratory function, delayed gastrointestinal recovery, increased sympathetic stimulation, myocardial stress, and prolonged hospital stay. Among the broad spectrum of surgical disciplines, open urological procedures - including radical nephrectomy, open pyeloplasty, radical cystectomy with urinary diversion, and open prostatectomy - impose a particularly significant postoperative pain burden. These operations involve wide flank, midline, or lower abdominal incisions and often require extensive retroperitoneal dissection, resulting in intense somatic and visceral pain that demands meticulous analgesic management.
The management of postoperative pain in urological surgery has historically relied on systemic opioids, most commonly administered via intravenous patient-controlled analgesia (PCA). While effective in controlling pain intensity, opioid-based regimens carry well-documented adverse effects including respiratory depression, postoperative nausea and vomiting (PONV), urinary retention, pruritus, sedation, and the longer-term risk of opioid dependence. These side effects are particularly problematic in the urological surgical population, which often includes elderly patients with pre-existing comorbidities and compromised renal reserve. This has driven a paradigm shift toward multimodal and opioid-sparing analgesic strategies.
Neuraxial analgesia - specifically continuous epidural infusion - has emerged as the reference standard for postoperative pain control in major open abdominal and pelvic surgery. Epidural analgesia delivered through an indwelling catheter provides analgesia superior to systemic opioids and reduces rates of pulmonary complications and postoperative ileus (Miller's Anesthesia, 10e). Among the local anesthetic agents used for continuous epidural infusion, ropivacaine has gained widespread acceptance as the preferred agent owing to its favorable profile: it is a pure (S)-enantiomer with a significantly lower risk of cardiovascular and central nervous system toxicity than racemic bupivacaine, offers a clinically useful degree of differential sensory-motor blockade, and has a duration of action comparable to bupivacaine (Goodman & Gilman's Pharmacological Basis of Therapeutics).
Dexmedetomidine, a highly selective alpha-2 (α2) adrenoreceptor agonist, represents a pharmacologically distinct approach to perioperative analgesia and sedation. Its analgesic mechanism operates through stimulation of α2C and α2A receptors in the dorsal horn of the spinal cord, directly suppressing pain transmission by reducing the release of pronociceptive transmitters - substance P and glutamate - and by hyperpolarizing interneurons. Administered as a continuous intravenous infusion, dexmedetomidine produces dose-dependent sedation, analgesia, and anxiolysis without causing clinically significant respiratory depression. Notably, in the postoperative setting, narcotic requirements are reduced by up to 50% when patients receive a dexmedetomidine infusion compared with placebo (Miller's Anesthesia, 10e). However, dexmedetomidine's sympatholytic activity and its effects on cardiovascular variables - potentially causing bradycardia, transient hypertension at loading, or sustained hypotension during infusion - present important hemodynamic considerations that must be weighed in the context of major urological surgery.

1.2 Rationale for the Study

The choice between continuous epidural ropivacaine infusion and intravenous dexmedetomidine infusion for postoperative analgesia in open urological surgery involves complex trade-offs. Epidural ropivacaine provides superior segmental analgesia, reduces neuroendocrine stress response, and spares systemic opioid consumption; however, it carries a risk of hemodynamic compromise through sympathetic blockade, and requires technical expertise and close monitoring. Dexmedetomidine offers systemic analgesia and sedation with an opioid-sparing effect, preserves respiratory drive, and provides sympatholytic hemodynamic stability; yet it lacks the depth of analgesia that neuraxial techniques afford for somatic pain and is associated with bradycardia and hypotension.
Despite a growing body of literature on each agent independently, head-to-head comparative data specifically evaluating ropivacaine epidural infusion versus dexmedetomidine intravenous infusion in the context of open urological surgery remain sparse. A 2026 review by Ahmadzadeh et al. noted that epidural block remains the benchmark analgesic technique for extensive open flank and pelvic urological operations, while newer regional and systemic alternatives are being evaluated. A 2021 study by Turki et al. demonstrated that epidural anesthesia combined with dexmedetomidine sedation for percutaneous nephrolithotomy significantly extended the time to first rescue analgesia (328 min vs. 72 min, p < 0.0001) and reduced PONV and shivering compared to general anesthesia. These findings highlight the compelling clinical questions that arise when neuraxial local anesthetic and systemic alpha-2 agonist approaches are compared in the urology operating context.

1.3 Aims and Objectives

Primary Aim: To compare the efficacy of continuous epidural ropivacaine infusion versus continuous intravenous dexmedetomidine infusion for postoperative pain management in patients undergoing open urological surgeries.
Secondary Aim: To assess hemodynamic stability, opioid consumption, adverse effects, and patient satisfaction in both groups.
Objectives:
  1. To evaluate and compare postoperative pain intensity using the Visual Analogue Scale (VAS) at defined time intervals (0, 2, 4, 6, 12, 24 hours postoperatively) in both groups.
  2. To compare intraoperative and postoperative hemodynamic parameters - heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) - between the two groups.
  3. To assess total opioid (rescue analgesia) consumption in the postoperative period in both groups.
  4. To compare the incidence of adverse effects including PONV, respiratory depression, pruritus, motor block, bradycardia, and hypotension between the two groups.
  5. To compare time to first rescue analgesia and duration of analgesia between the two groups.
  6. To evaluate postoperative sedation scores and patient satisfaction in both groups.

1.4 Hypothesis

Null Hypothesis (H₀): There is no significant difference in postoperative pain relief and hemodynamic stability between continuous epidural ropivacaine infusion and continuous intravenous dexmedetomidine infusion in patients undergoing open urological surgeries.
Alternate Hypothesis (H₁): There is a significant difference in postoperative pain relief and hemodynamic stability between continuous epidural ropivacaine infusion and continuous intravenous dexmedetomidine infusion in patients undergoing open urological surgeries.

CHAPTER 2: REVIEW OF LITERATURE

2.1 Postoperative Pain: An Overview

Postoperative pain is an expected physiological response to surgical injury and represents one of the most common complaints following any operative procedure. It results from nociceptive stimulation arising from tissue trauma, retraction, and inflammatory mediator release. The consequences of uncontrolled postoperative pain extend well beyond discomfort - impaired respiratory mechanics (splinting, reduced tidal volume, atelectasis), reduced mobility, sympathoadrenal activation, tachycardia, hypertension, hypercoagulability, delayed wound healing, and psychological distress all constitute downstream effects of inadequate analgesia. In the specific context of open urological surgery, pain arising from flank incisions and retroperitoneal dissection is predominantly somatic in character, while bladder and urethral manipulation introduces visceral pain components.
The goals of postoperative pain management are to provide adequate analgesia, minimize analgesic-related side effects, facilitate early mobilization, and support rapid return to baseline function. The American Society of Anesthesiologists (ASA) and the Enhanced Recovery After Surgery (ERAS) society advocate for multimodal analgesic strategies that combine regional techniques, systemic non-opioids, and opioid-sparing adjuvants to achieve these goals. Maingot's Abdominal Operations describes epidural analgesia as providing more complete analgesia than patient-controlled opioid analgesia throughout the postoperative course, and associates it with decreased rates of pulmonary complications and postoperative ileus.

2.2 Epidural Analgesia in Postoperative Pain Management

Epidural analgesia involves the insertion of a catheter into the epidural space, enabling the direct delivery of local anesthetics, opioids, or their combinations to spinal nerve roots, the dorsal root ganglion, or the spinal cord itself. The precise anatomical site of action within the epidural space for local anesthetics remains debated (Miller's Anesthesia, 10e). Continuous postoperative epidural analgesia has been established as superior to systemic opioids in several high-quality trials and meta-analyses for major abdominal and thoracic surgery.
The advantages of epidural analgesia include: elimination of systemic opioid requirements and their attendant side effects; reduction in the neuroendocrine stress response to surgery; improvement in gastrointestinal motility; and superior dynamic pain control (pain with movement), which is critical for early mobilization in the postoperative period. Potential complications include motor block (0.5-7%), hypotension from sympathetic blockade, epidural hematoma, and abscess (the latter occurring at a rate of approximately 0.5 per thousand) (Maingot's Abdominal Operations). The addition of low-dose epidural opioids to local anesthetic solutions enhances analgesia but increases the risk of PONV, pruritus, and respiratory depression.
Intraoperative use of the epidural catheter as part of a combined epidural-general anesthetic technique results in less pain and faster patient recovery immediately after surgery than general anesthesia followed by systemic opioids (Miller's Anesthesia, 10e). Ahmadzadeh et al. (2026) in their narrative review of regional analgesic techniques for urological surgery concluded that epidural block remains the "benchmark" for open flank surgery, providing superior pain scores and reduced opioid consumption compared to newer fascial plane blocks (quadratus lumborum block) for extensive open procedures.

2.3 Ropivacaine: Pharmacology and Clinical Profile

Ropivacaine (Naropin) is a long-acting, single (S)-enantiomer amide local anesthetic. It was developed to provide a safer alternative to racemic bupivacaine following reports of bupivacaine's significant cardiovascular toxicity, particularly with accidental intravascular injection. Ropivacaine differs from levobupivacaine in the substitution of a propyl group for the butyl group on the piperidine ring - a modification that reduces intrinsic cardiotoxicity (Miller's Anesthesia, 10e; Goodman & Gilman's).
Mechanism of action: Ropivacaine blocks voltage-gated sodium channels in axonal membranes, inhibiting the propagation of action potentials. The very slow reversal of Na+ channel blockade seen with bupivacaine after a cardiac action potential is considerably faster with ropivacaine, contributing to its more favorable cardiac safety profile. The negative inotropic potency of ropivacaine on isolated cardiac tissue is considerably less than that of bupivacaine (Miller's Anesthesia, 10e).
Differential sensory-motor blockade: A clinically important characteristic of ropivacaine is its tendency to produce more selective sensory blockade relative to motor blockade compared with equipotent doses of bupivacaine. This property is particularly desirable in the postoperative setting, where preservation of motor function is necessary for early ambulation. Goodman & Gilman's notes that ropivacaine "seems to be even more motor-sparing than bupivacaine."
Potency and duration: Ropivacaine is slightly less potent than bupivacaine (approximately 1:1.3 to 1:1.5 ratio) for epidural and regional anesthesia. It has a duration of action similar to that of bupivacaine, making it suitable for both surgical anesthesia and postoperative epidural infusion (Goodman & Gilman's). For epidural infusion, concentrations of 0.1-0.2% are commonly used, titrated to achieve adequate segmental analgesia.
Safety profile: Studies in animal models consistently demonstrate that bupivacaine more readily produces conduction disturbances, cardiac collapse, and ventricular fibrillation than ropivacaine, and that resuscitation after intentional intravenous injection is far more successful with ropivacaine (Miller's Anesthesia, 10e). Pfenninger and Fowler's Procedures for Primary Care notes that ropivacaine has a significantly higher threshold for CNS toxicity than bupivacaine.
Jayadevan et al. (2022) conducted an RCT evaluating 0.2% epidural ropivacaine at 5-8 mL/h in laparoscopic abdominal surgeries and found that the epidural ropivacaine group demonstrated superior intraoperative analgesia (fewer patients requiring additional fentanyl: 4 vs. 14, p=0.007) and improved postoperative pain scores at 6, 18, and 24 hours. However, epidural ropivacaine was associated with increased vasopressor use and prolonged ICU stay, emphasizing the need for careful hemodynamic monitoring with this technique [Jayadevan et al., J Anaesthesiol Clin Pharmacol, 2022, PMID 36171946].
Kumari et al. (2025) compared dexmedetomidine (1 µg/mL) and fentanyl (2 µg/mL) as adjuvants to 0.125% ropivacaine via patient-controlled epidural analgesia (PCEA) in 60 patients undergoing total abdominal hysterectomy. VAS pain scores were significantly lower in the ropivacaine-dexmedetomidine (RD) group at all time points from 4 to 24 hours postoperatively. Total drug consumption was also significantly lower in the RD group (138.47 ± 2.67 mL vs. 144.53 ± 4.19 mL, p=0.0001), with fewer self-administered bolus doses required. Hemodynamic parameters were comparable between groups, and no motor blockade or need for rescue analgesia was observed in either group [Kumari et al., Cureus, 2025, PMID 40755581].

2.4 Dexmedetomidine: Pharmacology and Clinical Profile

Dexmedetomidine is a highly selective alpha-2 (α2) adrenoreceptor agonist with a selectivity ratio for α2 vs. α1 receptors of approximately 1620:1 - significantly more α2-selective than clonidine. It is the dextro-isomer of medetomidine and is approved for sedation and analgesia in ICU and perioperative settings.
Mechanism of action: Dexmedetomidine acts as a nonselective α2-agonist on membrane-bound G-protein coupled α2-adrenoreceptors. Intracellular pathways include inhibition of adenylate cyclase and modulation of calcium and potassium ion channels. Three receptor subtypes have been described - α2A, α2B, and α2C - with the α2A subtype primarily distributed in the periphery and α2B and α2C located in the brain and spinal cord (Miller's Anesthesia, 10e). The analgesic effect is mediated through stimulation of α2C and α2A receptors in the dorsal horn, directly suppressing pain transmission by reducing the release of substance P and glutamate, and by hyperpolarizing interneurons.
Pharmacokinetics: Dexmedetomidine undergoes almost complete biotransformation via direct N-glucuronidation, hydroxylation (CYP2A6), and N-methylation to inactive metabolites. It is 94% protein bound. The elimination half-life is 2-3 hours, but the context-sensitive half-time ranges from 4 minutes after a 10-minute infusion to 250 minutes after an 8-hour infusion, which has important clinical implications for postoperative residual sedation. Renal impairment does not influence pharmacokinetics, though the sedative effect may be stronger in severe renal disease due to reduced plasma protein binding - an important consideration in the urological surgical population (Miller's Anesthesia, 10e).
Cardiovascular effects: Dexmedetomidine has significant effects on cardiovascular variables. An initial loading dose can produce transient hypertension and reflex bradycardia through peripheral α2B receptor stimulation causing vasoconstriction. With continued infusion and redistribution, central sympatholysis predominates, resulting in a sustained reduction in heart rate and blood pressure. This bradycardia and hypotension are dose-dependent and are the primary hemodynamic concerns during clinical use. Observed hypertension during loading may be avoided by decreasing the loading dose or increasing the time of administration (Miller's Anesthesia, 10e).
Analgesic and opioid-sparing effects: Systemic use of dexmedetomidine has a well-established opioid-sparing effect during surgery and postoperatively. In the postoperative ICU setting, narcotic requirements are reduced by 50% when patients are receiving a dexmedetomidine infusion compared with placebo (Miller's Anesthesia, 10e). Standard dosing for perioperative analgesia is a loading dose of 0.5-1 µg/kg over 10-15 minutes followed by a maintenance infusion of 0.2-0.7 µg/kg/h (Katzung's Basic and Clinical Pharmacology, 16e).
Dexmedetomidine as adjuvant in neuraxial and regional blocks: Dexmedetomidine has been investigated as an adjuvant to ropivacaine in nerve blocks, consistently demonstrating intensification and prolongation of sensory blockade. This effect is attributed to prolonged hyperpolarization of unmyelinated C-fibers (sensory), with lesser effect on A-fibers (motor), making it a useful sensory-selective adjuvant. When used caudally as an adjuvant to bupivacaine in children, dexmedetomidine reduces response to surgical stimulation and prolongs postoperative analgesia (Miller's Anesthesia, 10e).
Entezary et al. (2023) conducted an RCT in 46 patients undergoing thoracotomy, comparing postoperative epidural ropivacaine alone versus ropivacaine combined with dexmedetomidine. The combination group demonstrated significantly lower pain scores from 6-36 hours postoperatively and required significantly lower doses of rescue morphine (3.26 ± 0.90 mg vs. 7.04 ± 1.48 mg, p=0.035), concluding that the combination leads to lower postoperative pain scores and reduced opioid requirements [Entezary et al., Anesth Pain Med, 2023, PMID 37404259].

2.5 Hemodynamic Considerations in Open Urological Surgery

Open urological procedures such as radical nephrectomy, radical cystectomy, and open prostatectomy are major operations associated with significant intraoperative blood loss, extensive fluid shifts, and a prolonged postoperative course. The anesthesiologist must balance the analgesic benefit of neuraxial or systemic techniques against their hemodynamic consequences.
Epidural sympathetic blockade causes arteriolar and venous dilation in the blocked segments, leading to reduced systemic vascular resistance and venous return. The resulting hypotension is the most common complication of epidural analgesia and requires pre-emptive volume loading, judicious use of vasopressors, and careful catheter placement. The degree of hemodynamic compromise is related to the level of the block, the concentration of local anesthetic used, and the patient's baseline cardiovascular reserve.
Dexmedetomidine-induced hemodynamic effects are characterized by a biphasic response - initial transient hypertension followed by sustained reduction in heart rate and blood pressure due to central sympatholysis. In patients with significant underlying cardiovascular disease or autonomic dysregulation, this pattern requires vigilant monitoring.
Turki et al. (2021) studied epidural anesthesia combined with dexmedetomidine infusion versus general anesthesia for percutaneous nephrolithotomy (n=225). The epidural-dexmedetomidine group showed a significantly longer time to first rescue analgesia (328.17 ± 63.74 min vs. 72.09 min, p<0.0001), lower postoperative VAS scores at all time intervals, less PONV (6.1% vs. 13.6%), and greater patient satisfaction scores (8.75 ± 1.29 vs. 8.14 ± 1.39, p=0.001), demonstrating the combined technique's clinical effectiveness [PMID 35320957].
Ahmadzadeh et al. (2026), in their comparative analysis of QLB versus epidural blocks for urological surgeries, noted that epidural block groups consistently demonstrated more vasopressor interventions and a higher incidence of hemodynamic interventions compared to fascial plane blocks, particularly in radical cystectomy and nephrectomy - underscoring the hemodynamic challenge associated with epidural techniques for major urological operations [PMID 42029950].

2.6 Comparative Studies on Ropivacaine and Dexmedetomidine in Perioperative Pain

The growing interest in dexmedetomidine as a perioperative analgesic adjuvant has generated comparative literature against conventional neuraxial and systemic analgesics:
  • Dexmedetomidine vs. opioid adjuvants for epidural analgesia: Multiple studies have compared dexmedetomidine with fentanyl as adjuvants to epidural local anesthetics. Kumari et al. (2025) demonstrated the superiority of dexmedetomidine over fentanyl as an adjuvant to epidural ropivacaine for postoperative analgesia in abdominal surgery, with lower VAS scores and reduced drug consumption. The absence of motor blockade in the dexmedetomidine group is notable from a functional recovery standpoint.
  • Ropivacaine epidural vs. intravenous analgesics: Jayadevan et al. (2022) demonstrated that 0.2% epidural ropivacaine provided superior intraoperative and postoperative analgesia compared to intravenous fentanyl in laparoscopic abdominal surgery. However, the study highlighted the hemodynamic trade-off: increased vasopressor requirements and prolonged ICU stay in the epidural ropivacaine group.
  • Dexmedetomidine as epidural supplement: Entezary et al. (2023) showed that epidural dexmedetomidine combined with ropivacaine was more effective than ropivacaine alone post-thoracotomy, with a significant reduction in rescue opioid requirements.
  • Dexmedetomidine for urological procedures: Turki et al. (2021) validated the use of epidural anesthesia with dexmedetomidine sedation infusion as an effective and superior alternative to general anesthesia for percutaneous nephrolithotomy, with favourable analgesic and safety profiles.

2.7 Enhanced Recovery After Surgery (ERAS) in Urological Surgery

ERAS protocols for major urological procedures - particularly radical cystectomy and nephrectomy - have increasingly incorporated multimodal analgesic strategies as a central pillar. These include preoperative patient education and optimization, intraoperative neuraxial analgesia, systemic non-opioid adjuvants (NSAIDs, acetaminophen, gabapentinoids), and minimizing routine opioid prescriptions. The choice of postoperative analgesic technique profoundly influences ERAS outcomes - particularly time to first oral intake, early mobilization, length of hospital stay, and 30-day readmission rates.
Ziegelmann et al. (2019) documented wide variation in opioid prescribing patterns after urological surgery across tertiary care centres, noting that standardization of analgesic protocols - incorporating regional and non-opioid techniques - was needed to reduce opioid-related morbidity [PMID 30711124]. Anderson et al. (2022) further emphasized the urgency of opioid-sparing strategies in urology, given the risk of opioid dependence in the postoperative surgical population [PMID 36118983].

2.8 Summary and Research Gap

The existing literature supports the efficacy of both continuous epidural ropivacaine infusion and intravenous dexmedetomidine infusion as components of postoperative analgesic regimens in major abdominal surgery. However, direct comparative data specifically evaluating these two distinct approaches - epidural ropivacaine versus IV dexmedetomidine infusion - as the primary postoperative analgesic modality in open urological surgery are lacking. Most published studies either combine dexmedetomidine as an adjuvant to epidural local anesthetics rather than comparing it as a standalone systemic alternative, or are conducted in non-urological surgical populations (thoracotomy, abdominal hysterectomy, laparoscopic cholecystectomy). The differences in their mechanisms of action, routes of administration, hemodynamic consequences, and side-effect profiles make a head-to-head comparison in the urological surgical setting both clinically relevant and scientifically necessary. This study aims to fill this gap.
Key References Cited:
  1. Miller's Anesthesia, 2-Volume Set, 10e - Continuous Epidural Analgesia, Dexmedetomidine Pharmacology
  2. Goodman & Gilman's The Pharmacological Basis of Therapeutics - Ropivacaine
  3. Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e - Epidural Analgesia
  4. Katzung's Basic and Clinical Pharmacology, 16e - Dexmedetomidine dosing
  5. Maingot's Abdominal Operations - Epidural vs. PCA analgesia
  6. Ahmadzadeh S et al. (2026). Comparative Analysis of Quadratus Lumborum Versus Epidural Blocks for Postoperative Pain Management in Urologic Surgeries. Curr Pain Headache Rep. [PMID 42029950]
  7. Turki S et al. (2021). A Comparative Study of Epidural Anesthesia with Dexmedetomidine Infusion versus General Anesthesia for Percutaneous Nephrolithotomy. Anesth Essays Res. [PMID 35320957]
  8. Jayadevan D et al. (2022). Evaluation of analgesic effects and hemodynamic responses of epidural ropivacaine in laparoscopic abdominal surgeries. J Anaesthesiol Clin Pharmacol. [PMID 36171946]
  9. Entezary SR et al. (2023). Effect of Epidural Infusion of Dexmedetomidine on Postoperative Analgesia After Thoracotomy. Anesth Pain Med. [PMID 37404259]
  10. Kumari P et al. (2025). Comparison of Dexmedetomidine and Fentanyl as Adjuvants to Ropivacaine for Epidural Analgesia in Abdominal Hysterectomy. Cureus. [PMID 40755581]
  11. Ziegelmann MJ et al. (2019). Wide Variation in Opioid Prescribing After Urological Surgery. Mayo Clin Proc. [PMID 30711124]
  12. Anderson DJ et al. (2022). Opioids in Urology: How Well Are We Preventing Opioid Dependence? Health Psychol Res. [PMID 36118983]
A note on using this draft: The citations above include both textbook sources and PubMed-verified journal articles with correct PMIDs. You should obtain full-text access to the key RCTs (especially PMIDs 35320957, 36171946, 37404259, 40755581) and cite them in the Vancouver format required by your institution. The sections on aims/objectives and the hypothesis should be adapted to match your institutional thesis format guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.